Amedeo Smart

Free Medical Literature Service


 

Amedeo

Hepatitis C

  Free Subscription

Articles published in
J Med Virol
    September 2022
  1. ADEBOYEJO K, King B, Tsoleridis T, Tarr A, et al
    Hepatitis C subtyping assay failure in UK patients born in Sub-Saharan Africa: implications for global treatment and elimination.
    J Med Virol. 2022 Sep 27. doi: 10.1002/jmv.28178.
    >> Share

    July 2022
  2. RUPASINGHE D, Choi JY, Yunihastuti E, Kiertiburanakul S, et al
    Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28019.
    >> Share

    June 2022
  3. OHTA A, Ogawa E, Murata M, Matsumoto Y, et al
    Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27904.
    >> Share

    May 2022
  4. ZENG QL, Yu ZJ, Lv J, Zhang HX, et al
    Sofosbuvir-based Therapy for Late Pregnant Women and Infant with Severe Chronic Hepatitis C: A Case Series Study.
    J Med Virol. 2022 May 20. doi: 10.1002/jmv.27877.
    >> Share

  5. XIE Z, Deng K, Xia Y, Zhang C, et al
    Efficacy and safety of direct-acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: a multi-center, real-world study in Guangdong, China.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27851.
    >> Share

  6. MALONGA GA, Dienta S, Traore FT, Maiga Z, et al
    Human Herpesvirus 8 seroprevalence among blood donors in Mali.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27850.
    >> Share

    January 2022
  7. LEON FJF, Silva LLD, Santos AC, Duarte da Costa V, et al
    Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus.
    J Med Virol. 2022 Jan 22. doi: 10.1002/jmv.27614.
    >> Share

    November 2021
  8. BOLINA-SANTOS E, Chaves DG, da Silva-Malta MCF, Carmo RA, et al
    HCV infection in hemophilia A patients is associated with altered cytokines and chemokines profile and might modulate the levels of FVIII inhibitor.
    J Med Virol. 2021 Nov 5. doi: 10.1002/jmv.27432.
    >> Share

    October 2021
  9. JI Q, Chu X, Zhou Y, Liu X, et al
    Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.
    J Med Virol. 2021 Oct 2. doi: 10.1002/jmv.27374.
    >> Share

    September 2021
  10. KAZMI SK, Khan FMA, Natoli V, Hunain R, et al
    Viral hepatitis amidst COVID-19 in Africa: Implications and Recommendations.
    J Med Virol. 2021 Sep 10. doi: 10.1002/jmv.27330.
    >> Share

  11. NICOLINI LA, Menzaghi B, Molteni C, Vichi F, et al
    Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27329.
    >> Share

    August 2021
  12. ZHOU R, Liu L, Wang Y
    Viral Proteins Recognized by Different TLRs.
    J Med Virol. 2021 Aug 10. doi: 10.1002/jmv.27265.
    >> Share

    July 2021
  13. WEI MT, Le MH, Landis C, Trinh H, et al
    Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C.
    J Med Virol. 2021 Jul 5. doi: 10.1002/jmv.27168.
    >> Share

    June 2021
  14. LEUMI S, El Kassas M, Zhong J
    Hepatitis C virus-genotype 4: a poorly characterized endemic genotype.
    J Med Virol. 2021 Jun 29. doi: 10.1002/jmv.27165.
    >> Share

  15. TADA T, Kurosaki M, Nakamura S, Hasebe C, et al
    Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27157.
    >> Share

    April 2021
  16. BULFONI M, Pravisani R, Dalla E, Cesselli D, et al
    miRNA expression profiles in liver grafts of HCV and HIV/HCV infected recipients, six months after liver transplantation.
    J Med Virol. 2021 Apr 5. doi: 10.1002/jmv.26999.
    >> Share

    March 2021
  17. ELHENCE A, Singh A, Anand A, Kumar R, et al
    Real-World Re-Treatment Outcomes of Direct-Acting Antiviral Therapy Failure in Patients with Chronic Hepatitis C.
    J Med Virol. 2021 Mar 30. doi: 10.1002/jmv.26971.
    >> Share

  18. FEDORCHENKO SV, Martynovych T, Klimenko Z, Solianyk I, et al
    Effectiveness of retreatment with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin in patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous with first- and second-generation NS5A inhibitors.
    J Med Virol. 2021 Mar 11. doi: 10.1002/jmv.26935.
    >> Share

    December 2020
  19. MIRANDA NTGP, de Souza RL, Monteiro JC, Costa IB, et al
    Seroprevalence of HBV and HCV in female sex workers from four cities in the state of Para, northern Brazil.
    J Med Virol. 2020 Dec 25. doi: 10.1002/jmv.26759.
    >> Share

    November 2020
  20. CHUA JV, Ntem-Mensah A, Abutaleb A, Husson J, et al
    Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: an open-label study.
    J Med Virol. 2020 Nov 5. doi: 10.1002/jmv.26652.
    >> Share

    September 2020
  21. HIGUCHI M, Tamaki N, Kurosaki M, Inada K, et al
    Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic Hepatitis C.
    J Med Virol. 2020 Sep 5. doi: 10.1002/jmv.26490.
    >> Share

    August 2020
  22. KUMAR R, Chan KP, Ekstrom VSM, Wong JCC, et al
    Hepatitis C Virus antigen detection is an appropriate test for screening and early diagnosis of hepatitis C virus infection in at-risk populations and immunocompromised hosts.
    J Med Virol. 2020 Aug 14. doi: 10.1002/jmv.26433.
    >> Share

  23. RIDRUEJO E, Pinero F, Mendizabal M, Cheinquer H, et al
    Decompensated cirrhosis and liver transplantation negatively impact in DAA treatment response: Real-world experience from HCV-LALREAN cohort.
    J Med Virol. 2020 Aug 4. doi: 10.1002/jmv.26383.
    >> Share

    July 2020
  24. FAROOQ M, Rauf M, Tahir F, Manzoor S, et al
    "A comparative analysis of interferons and direct-acting antivirals on the expression of genes involved in hepatitis C pathogenesis".
    J Med Virol. 2020 Jul 24. doi: 10.1002/jmv.26351.
    >> Share

    June 2020
  25. HAN W, Li J, Zhou H, Qian J, et al
    Identification of the association of CD28(+) CD244(+) Tc17/IFN-gamma cells with chronic hepatitis C virus infection.
    J Med Virol. 2020 Jun 22. doi: 10.1002/jmv.26205.
    >> Share

  26. ABO EL-KHAIR SM, El-Alfy HA, Elsamanoudy AZ, Elhammady D, et al
    Development of a novel glycated protein-based fibrosis prediction score for determination of significant liver fibrosis in HCV-infected patients, a preliminary study.
    J Med Virol. 2020 Jun 19. doi: 10.1002/jmv.26204.
    >> Share

  27. XIAO L, Wu X, Zhang F, Wang J, et al
    Changes of inflammatory cytokines/chemokines during ravidasvir plus ritonavir-boosted danoprevir and ribavirin therapy for patients with genotype 1 b hepatitis C infection.
    J Med Virol. 2020 Jun 11. doi: 10.1002/jmv.26161.
    >> Share

  28. SEBASTIAO CS, Neto Z, Jandondo D, Mirandela M, et al
    HIV, hepatitis B virus, hepatitis C virus, and syphilis among pregnant women attending antenatal care in Luanda, Angola: seroprevalence and risk factors.
    J Med Virol. 2020 Jun 9. doi: 10.1002/jmv.26148.
    >> Share

    May 2020
  29. MOHAMADI M, Azarbayjani K, Mozhgani SH, Bamdad T, et al
    Hepatitis C virus alternative reading frame protein (ARFP): production, features and pathogenesis.
    J Med Virol. 2020 May 29. doi: 10.1002/jmv.26091.
    >> Share

  30. WAHID B, Shami K, Joiya SA, Ozuyar SEG, et al
    Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin).
    J Med Virol. 2020 May 17. doi: 10.1002/jmv.25931.
    >> Share

  31. WATANABE T, Tokumoto Y, Joko K, Michitaka K, et al
    Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection.
    J Med Virol. 2020 May 6. doi: 10.1002/jmv.25984.
    >> Share

    April 2020
  32. JAMIL Z, Waheed Y, Ahsan O, Najmi MH, et al
    Familial Clustering of Hepatitis C Virus in Pakistani Population.
    J Med Virol. 2020 Apr 22. doi: 10.1002/jmv.25926.
    >> Share

    March 2020
  33. JAMSHIDI S, Bokharaei-Salim F, Esghaei M, Bastani MN, et al
    Occult HCV and Occult HBV Co-infection in Iranian Human Immunodeficiency Virus-Infected Individuals.
    J Med Virol. 2020 Mar 31. doi: 10.1002/jmv.25808.
    >> Share

  34. MARGUSINO-FRAMINAN L, Perez EB, Cid-Silva P, Rodriguez-Sotelo A, et al
    Effectiveness and Safety of Direct-Acting Antivirals in Hepatitis C Infected Patients with Mental Disorders: Results in Real Clinical Practice.
    J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25772.
    >> Share

  35. MUSHTAQ S, Mansoor A, Umar M, Khan A, et al
    Direct-acting antiviral agents in the treatment of chronic Hepatitis C - Real-life experience from clinical practices in Pakistan.
    J Med Virol. 2020 Mar 4. doi: 10.1002/jmv.25745.
    >> Share

    February 2020
  36. LU C, Feng Y, Sun X, Li N, et al
    Tree Shrew Bone Marrow-Derived Mesenchymal Stem Cells Express CD81, OCLN, and miR-122, Facilitating the Entire Hepatitis C Virus Life Cycle.
    J Med Virol. 2020 Feb 13. doi: 10.1002/jmv.25710.
    >> Share

    December 2019
  37. FUCHS M, Monto A, Brau N, Charafeddine M, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin for Chronic HCV Infection in US Veterans with Psychiatric Disorders.
    J Med Virol. 2019 Dec 12. doi: 10.1002/jmv.25655.
    >> Share

  38. KIM M, Kyung Lee Y, Park B, Jun Oh D, et al
    Hepatitis virus B and C infections are associated with an increased risk of non-Hodgkin lymphoma: A nested case-control study using a national sample cohort.
    J Med Virol. 2019 Dec 11. doi: 10.1002/jmv.25653.
    >> Share

    November 2019
  39. OMRAN NM, El-Sherbini SM, Hegazy O, Elshaarawy AA, et al
    Crosstalk between miR-215 and Epithelial-Mesenchymal Transition (EMT) specific markers (E- and N-cadherin) in different stages of chronic HCV Infection.
    J Med Virol. 2019 Nov 26. doi: 10.1002/jmv.25637.
    >> Share

  40. DEL-RIOS NHA, de Araujo LA, Martins RMB, Guimaraes RA, et al
    Molecular and Epidemiological Aspects of Hepatitis C Virus Infection Among Crack Cocaine Users.
    J Med Virol. 2019 Nov 20. doi: 10.1002/jmv.25632.
    >> Share

    October 2019
  41. GRABARCZYK P, Kubicka-Russel D, Kopacz A, Liszewski G, et al
    Seronegative hepatitis C virus (HCV) infection in Polish blood donors - virological characteristics of index donations and follow-up observations.
    J Med Virol. 2019 Oct 31. doi: 10.1002/jmv.25617.
    >> Share

  42. MAHMUD S, Chemaitelly HS, Kouyoumjian SP, Kanaani ZA, et al
    Key associations for hepatitis C virus genotypes in the Middle East and North Africa.
    J Med Virol. 2019 Oct 30. doi: 10.1002/jmv.25614.
    >> Share

  43. TSAI TC, Deng ST, Hsu CW
    The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan.
    J Med Virol. 2019 Oct 10. doi: 10.1002/jmv.25605.
    >> Share

  44. SAITO Y, Imamura M, Uchida T, Osawa M, et al
    Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    J Med Virol. 2019 Oct 4. doi: 10.1002/jmv.25602.
    >> Share

    April 2019
  45. EL KASSAS M, Alboraie M, Omar H, El Latif YA, et al
    High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results.
    J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25478.
    >> Share

    January 2019
  46. KWEON OJ, Lim YK, Kim HR, Kim TH, et al
    Analytical Performance of Newly Developed Rapid Point-of-Care Test for the Simultaneous Detection of Hepatitis A, B, and C Viruses in Serum Samples.
    J Med Virol. 2019 Jan 22. doi: 10.1002/jmv.25405.
    >> Share

    October 2018
  47. YANG H, Wu J, Yuan Y, Huang W, et al
    Retrospectively Seroprevalence Study on Anti-HEV-IgG antibody in patients with chronic hepatitis or liver cirrhosis in a Chinese teaching hospital.
    J Med Virol. 2018 Oct 11. doi: 10.1002/jmv.25335.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016